Compared with treatments of anti-PD-1/PD-L1 regimens combined with various of other systemic therapies involving cytotoxic T lymphocyte-associated antigen-4 antibody, multi-kinase or anti-angiogenesis agents, anti-PD-1/PD-L1 therapies plus radiation have demonstrated a higher tumor response rate (52.8% vs. 24–32% according to RECIST, 75.0% vs. 30.0–46.0% according to mRECIST), better disease control (98.1% vs. 75% according to mRECIST), and longer PFS (12.6 months vs. 2.2–6.9 months) (7, 8, 10, 14, 22, 25) (29). The gene discussed is CTLA4; the disease is neoplasm.